Search

Your search keyword '"Kraxner, Helga"' showing total 94 results

Search Constraints

Start Over You searched for: Author "Kraxner, Helga" Remove constraint Author: "Kraxner, Helga"
94 results on '"Kraxner, Helga"'

Search Results

1. MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases

2. Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study

3. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

4. Impairment of EQ-5D-5L Domains According to Allergic Rhinitis and Asthma Control: A MASK-air Real-World Study

5. Cutoff Values of MASK-air Patient-Reported Outcome Measures

6. Poor rhinitis and asthma control is associated with decreased health-related quality-of-life and utilities: A MASK-air study

7. MASK-air®: An OECD (Organisation for Economic Coordination and Development) Best Practice for Public Health on integrated care for chronic diseases.

8. Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

9. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air approach.

10. Consistent trajectories of rhinitis control and treatment in 16,177 weeks : the MASK-air® longitudinal study

11. Patient-centered digital biomarkers for allergic respiratory diseases and asthma:The ARIA-EAACI approach – ARIA-EAACI Task Force Report

12. Patient‐centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA‐EAACI approach

13. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air (R) longitudinal study

14. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

15. Consistent trajectories of rhinitis control and treatment in 16,177 weeks

17. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

18. Cutoff Values of MASK-air Patient-Reported Outcome Measures

19. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK‐air® longitudinal study

20. The ARIA-MASK-air® approach

21. A study using MASK-air® real-world data

22. Comparison of rhinitis treatments using MASK ‐air® data and considering the minimal important difference

23. Results of a Bayesian mixed-effects model

24. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference

25. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air real-world data.

26. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.

27. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference.

28. Comparison of rhinitis treatments using MASK-air (R) data and considering the minimal important difference

29. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

30. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air(R) real-world data

31. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK‐air ® real‐world data

32. Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model

33. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

34. Management of anaphylaxis due to COVID‐19 vaccines in the elderly

35. Management of anaphylaxis due to COVID-19 vaccines in the elderly

36. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)

37. ARIA-EAACI statement on Asthma and COVID-19 (June 2, 2020)

40. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

41. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19

43. ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)

44. ARIA masterclass 2018: From guidelines to real-life implementation

48. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.

49. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy.

50. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).

Catalog

Books, media, physical & digital resources